N -acetyl serotonin derivatives as potent neuroprotectants for retinas
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
N-acetylserotonin (NAS) is synthesized from serotonin by arylalkylamine N -acetyltransferase (AANAT), which is predominantly expressed in the pineal gland and retina. NAS activates TrkB in a circadian manner and exhibits antidepressant effects in a TrkB-dependent manner. It also enhances neurogenesis in hippocampus in sleep-deprived mice. Here we report the identification of NAS derivatives that possess much more robust neurotrophic effects with improved pharmacokinetic profiles. The compound N -[2-(5- h ydroxy-1H- i ndol-3-yl)ethyl]-2- o xopiperidine-3- c arboxamide (HIOC) selectively activates TrkB receptor with greater potency than NAS. It potently protects retinas from light-induced retinal degeneration (LIRD), which is tightly coupled with pronounced TrkB activation in retinas. Pharmacokinetic studies demonstrate that this compound is stable in serum and liver microsomes. It can pass the blood–brain barrier and blood–retinal barrier. Hence, HIOC is a good lead compound for further drug development for treating retinal degenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944 · cited 1×
“BDNF binding to TrkB triggers its dimerization and autophosphorylation of tyrosine residues in its intracellular domain, leading to activation of the three major downstream signaling cascades, including mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ1 (PLC-γ1) (8, 9…”
BackgroundPoduslo, J. F., & Curran, G. L. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00250-v · Cited by 614
Cited by
Longo, F. M., & Massa, S. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4024 · Cited by 298
TrkB Receptor Signalling: Implications in Neurodegenerative, Psychiatric and Proliferative Disorders
Gupta, V., You, Y., Gupta, V., Klistorner, A., & Graham, S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140510122 · Cited by 258
TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury
Wang, Y., Liang, J., Xu, B., Yang, J., Wu, Z., & Cheng, L. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122282 · Cited by 152
Pankiewicz, P., Szybiński, M., Kisielewska, K., Gołębiowski, F., Krzemiński, P., Rutkowska-Włodarczyk, I., Moszczyński-Pętkowski, R., Gurba-Bryśkiewicz, L., Delis, M., Mulewski, K., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14080704 · Cited by 42
Small-Molecule Trk Agonists: Where Do We Go from Here?
Thompson, T. S., Sefiani, A., & Burgess, K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02365 · Cited by 13
Metadata
- Authors
- Shen, J., Ghai, K., Sompol, P., Liu, X., Cao, X., Iuvone, P. M., & Ye, K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-02-13
- Volume
- 109
- Issue
- 9
- Pages
- 3540-3545
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1998349911
- Cited by
- 51
- References
- 2
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: N -acetyl serotonin derivatives as potent neuroprotectants for retinas. https://app.cochat.ai/papers/10.1073/pnas.1119201109
- The paper
- Shen, J., Ghai, K., Sompol, P., Liu, X., Cao, X., Iuvone, P. M., & Ye, K. (2012). N -acetyl serotonin derivatives as potent neuroprotectants for retinas. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1119201109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.